Pay in 4 interest-free payments of $6.28 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
No amount of dose adjustment can compensate for that magnitude of difference
to bring widely used but legally ambiguous compounds into the regulated marketplace
The first randomized, double-blind, placebo-controlled phase 2 study to evaluate the efficacy and safety of an FcRn inhibitor, rozanolixizumab, in patients with leucine-rich gliomainactivated 1 autoimmune encephalitis
The protocol is flexible enough to serve both goals
If you have questions about technique, ask your medical team for training before your first dose
US$ 29.53
US$ 27.26
US$ 22.33
